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Abstract
B vitamins involved in one-carbon metabolism have been implicated in the development of inflammation- and angiogenesis-related chronic
diseases, such as colorectal cancer (CRC). Yet, the role of one-carbon metabolism in inflammation and angiogenesis among CRC patients
remains unclear. The objective of this study was to investigate associations of components of one-carbon metabolism with inflammation
and angiogenesis biomarkers among newly diagnosed CRCpatients (n 238) in the prospective ColoCare Study, Heidelberg.We cross-sectionally
analysed associations between twelve B vitamins and one-carbon metabolites and ten inflammation and angiogenesis biomarkers from
pre-surgery serum samples using multivariable linear regression models. We further explored associations among novel biomarkers in these
pathways with Spearman partial correlation analyses. We hypothesised that pyridoxal-5’-phosphate (PLP) is inversely associated with inflam-
matory biomarkers. We observed that PLP was inversely associated with C-reactive protein (CRP) (r –0·33, Plinear< 0·0001), serum amyloid
A (SAA) (r –0·23, Plinear= 0·003), IL-6 (r –0·39, Plinear< 0·0001), IL-8 (r –0·20, Plinear= 0·02) and TNFα (r –0·12, Plinear= 0·045). Similar findings
were observed for 5-methyl-tetrahydrofolate and CRP (r –0·14), SAA (r –0·14) and TNFα (r –0·15) among CRC patients. Folate catabolite
acetyl-para-aminobenzoylglutamic acid (pABG) was positively correlated with IL-6 (r 0·27, Plinear< 0·0001), and pABG was positively
correlated with IL-8 (r 0·21, Plinear< 0·0001), indicating higher folate utilisation during inflammation. Our data support the hypothesis of
inverse associations between PLP and inflammatory biomarkers among CRC patients. A better understanding of the role and inter-relation
Abbreviations: apABG, acetyl-para-aminobenzoylglutamic acid; CRC, colorectal cancer; CRP, C-reactive protein; FA, folic acid; GGM, Gaussian graphical model;
HK:XA ratio, 3-hydroxykynurenine:xanthurenic acid ratio; mTHF, 5-methyl-tetrahydrofolate; PA, pyridoxic acid; pABG, para-aminobenzoylglutamic acid; PL,
pyridoxal; PLP, pyridoxal-5’-phosphate; SAA, serum amyloid A; VEGF, vascular endothelial growth factor.
* Corresponding authors: Mary Playdon, email mary.playdon@hci.utah.edu; Cornelia M. Ulrich, email neli.ulrich@hci.utah.edu
† These authors contributed equally to this work.
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of PLP and other one-carbon metabolites with inflammatory processes among colorectal carcinogenesis and prognosis could identify targets for
future dietary guidance for CRC patients.
Key words: One-carbon metabolism: B vitamins: Folate: Vitamin B6: Inflammation: Colorectal cancer: Angiogenesis
Colorectal cancer (CRC) is the third most common cancer
among men and the second most common cancer among
women worldwide, contributing to >200 000 deaths in 2018
in Europe(1). There is accumulating evidence that up to 50 %
of all CRC cases may be preventable through diet, physical
activity and being a healthy body weight(2) and that diet could
be an important predictor of CRC recurrence and survival(3,4).
To date, there are no evidence-based dietary guidelines for
CRC survivors and it is recommended to follow the guidelines
for cancer prevention(2), including reducing processed meat
and alcohol consumption. Evidence is limited for other
nutrients and foods(2). Few studies have evaluated dietary
intake after CRC diagnosis, whether by dietary recall or dietary
biomarkers, nor its association with CRC outcomes. Nonethe-
less, emerging data suggest that dietary factors implicated
in colorectal carcinogenesis may not have the same impact
on CRC progression and invasion; thus, further research is
needed to support the evidence base for CRC dietary guidance
post-diagnosis(5). With the increasing rates of CRC among
younger adults <50 years and the increasing prevalence of
CRC survivors in Europe(6), the development of dietary recom-
mendations for this population is of major public health
relevance.
Evaluating the association of dietary factors with biological
pathways implicated in CRC cancer progression among CRC
patients may shed light on potential strategies for intervention
to improve prognosis. Important pathways in the development,
promotion and progression of CRC include inflammation(7–11)
and angiogenesis(12,13). Inflammatory bowel diseases and obesity,
two strong CRC risk factors, promote inflammation, whereas
non-steroidal anti-inflammatory drugs are associated with lower
CRC risk(7–9). Inflammatory chemokines are immune modulators
that promote angiogenesis, a key feature of tumour progression,
supported by vascular endothelial growth factors (VEGF)(12,13).
Modulation of one-carbon metabolites that serve many biological
functions(14) (e.g. vitamin B6 and folate) has been shown to lower
circulating inflammatory biomarkers in non-cancer popula-
tions(15), though the role of B vitamins in angiogenesis is less clear.
The interrelationship of inflammation, angiogenesis and
components of one-carbon metabolism with colorectal carcino-
genesis among CRC patients and survivors remains inconclusive.
Indeed, the role of nutrient metabolism in cancer is complex. For
example, a U-shaped relationship between micronutrients and
cancer is evident where supplementation among those with
deficiency is associated with reduced cancer risk, but among
those with sufficient or higher micronutrient status may promote
cancer growth(16). Considering this complexity, we sought to
better characterise the nature of the relationship between one-
carbonmetabolites and pathways integral to cancer progression.
Few studies have evaluated post-diagnosis circulating one-
carbon metabolites in relation to cancer prognostic pathways
among CRC patients(17).
Our objective was to evaluate associations between
inflammation- and angiogenesis-related biomarkers and one-
carbon metabolites among CRC survivors. Based on prior
findings(15,18–20), we hypothesised that pyridoxal-5’-phosphate
(PLP) is inversely associated with pro-inflammatory biomarkers
C-reactive protein (CRP), serum amyloid A (SAA), TNFα and
IL-6 and IL-8 among CRC patients. We further hypothesised that
5-methyl-tetrahydrofolate (mTHF) inversely associates with
inflammatory biomarkers corresponding to higher production
of folate catabolites para-aminobenzoylglutamic acid (pABG)
and acetyl-pABG (apABG) in this population.
Subjects and methods
Study design
This is a cross-sectional analysis of baseline data from the
ColoCare Study, a multicentre, international prospective cohort
initiated at the Fred Hutchinson Cancer Research Center (Seattle,
WA, USA), described in detail in prior publications(21–23).
ColoCare recruits newly diagnosedCRC patients prior to surgery,
with the goal to investigate predictors of cancer recurrence,
survival, treatment toxicities and health-related QoL.
Patients (eligibility: newly diagnosed primary invasive CRC,
aged 18–89 years,German-speakingand able toprovide informed
consent) from the ColoCare Heidelberg site were included in this
study, recruited betweenOctober 2010 andDecember 2014 at the
University Hospital of Heidelberg, Germany (ClinicalTrials.gov
Identifier: NCT02328677). Participants were staged according to
the American Joint Committee on Cancer (AJCC) system based
on histopathological findings. Both patients with colon (ICD-10
C18) and rectal or recto-sigmoid junction cancer (ICD-10 C19/
C20) were included. The ColoCare Study has been approved
by the ethics committee of the Medical Faculty at the
University ofHeidelberg.All studyparticipants providedwritten
informed consent.
Study population
In total, 356 stage I–IV CRC patients have been recruited into the
ColoCare Study in Heidelberg (online Supplementary Fig. S1).
For this project, we excluded patients who did not have all
measured biomarkers of interest, with 238 CRC patients included
in the current analysis. Patients with a history of hereditary
nonpolyposis CRC or familial adenomatous polyposis were
not excluded from the study. According to estimates(24), approx-
imately 1 % of our participants were likely to have familial
adenomatous polyposis and 2–4 % to have hereditary nonpoly-
posis CRC. The fact that non-steroidal anti-inflammatory drugs
intervention prevents tumours among individuals with genetic
predisposition to CRC (e.g. in the case of Lynch syndrome)(25,26)
suggests that inflammatory pathways remain an important
target for this population, and therefore the relationship of
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inflammation with other cancer-related molecular pathways
remains of interest among individuals with or without germline
mutations. ColoCare participants were also part of the inter-
national FOlate-dependent one-carbon metabolism in Colorectal
cancer recUrrence and Survival (FOCUS) Consortium.
Circulating inflammation and angiogenesis biomarkers
Non-fasting blood samples were collected at baseline prior to
surgery at the University Hospital Heidelberg. Blood samples
were collected 1·3 (SD 1·25) d before surgery, on average.
Samples were frozen 6·3 (SD 7·1) h following blood draw and
stored for approximately 5·5 years. Serum was extracted within
4 h of blood draw, and aliquots were stored at –80°C until analy-
sis. Aliquots (500 μl) were shipped on dry ice from Heidelberg
to the Huntsman Cancer Institute, Salt Lake City, UT, USA. Ten
inflammation biomarkers, including CRP, SAA, TNFα, IL-6,
IL-8, monocyte chemoattractant protein 1 (MCP-1), soluble inter-
cellular adhesionmolecule 1 (sICAM-1) and soluble vascular cell
adhesion molecule 1 (sVCAM-1), and angiogenesis-related bio-
markers, including VEGF-A and VEGF-D were measured in
serum. Previously established assays on the Mesoscale
Discovery Platform (MSD), on the Sector 2400A, were used in
the Ulrich laboratory at the Huntsman Cancer Institute(27).
Blinded patient samples, intraplate and interplate quality control
samples were run on the U-PLEX Proinflammatory Combo 1 for
MCP-1, IL-6, IL-8, and TNFα, on the V-PLEX Vascular Injury Plate
2 for CRP, SAA, sICAM-1 and sVCAM-1, and on the V-PLEX
Angiogenesis Panel 1 for VEGF-A and VEGF-D. Blinded serum
samples were diluted 1:2 (pro-inflammatory panel), 1:1000
(vascular injury plate) and 1:8 (angiogenesis panel). For the vas-
cular injury and angiogenesis panels, the samples were freeze-
thawed once and the pro-inflammatory panel was freeze-thawed
twice. The plates were read with an MSD sector 2100A, and data
analyses were carried out with MSD Discovery Workbench 4.0
software (Meso ScaleDiagnostics). The resulting overall interplate
CV was 9·9% (range 5·1–15·5%) and intraplate CV was 4·6%
(range 1·8–6·4%).
B vitamins and one-carbon metabolites
Twelve B vitamins and one-carbon metabolites were measured
in non-fasting blood samples collected at baseline prior to
surgery, including PLP, pyridoxal (PL), pyridoxic acid (PA),
mTHF, apABG, pABG, folic acid (FA), thiamine, thiamine mono-
phosphate, riboflavin, cobalamin and homocysteine. After
serum extraction, aliquots were stored at −80°C. Assays were
run at the laboratory BEVITAL A/S, Bergen, Norway (www.
bevital.no), as part of analyses run for the FOCUS consortium.
Biological analyses were performed on seven complementary
analytical platforms, using liquid chromatography-tandem MS-
based assays (LC-MS/MS) and GC-MS/MS(28). Within-day and
between-day CV ranged between 1–9 and 2–16 %, respectively.
Statistical analysis
Descriptive statistics of the study population were calculated
for clinical characteristics. Means and standard deviations were
computed for normally distributed continuous variables, medi-
ans and interquartile ranges for right-skewed variables
(inflammation, angiogenesis and one-carbon metabolism bio-
markers) and frequencies (n, (%)) for categorical variables.
Categorical variables with more than two classes were consid-
ered in our analyses as indicator variables. Distributions of var-
iables were analysed using q-q plots and histograms along with
measurement of skewness and kurtosis. One-carbon metabo-
lism, inflammation- and angiogenesis-related biomarkers were
log2-transformed to meet the normality assumption for paramet-
ric statistical tests. No outliers, defined as three times SD above or
below the mean value, accounting for multivitamin intake, were
found. For data flagged as missing by the laboratory due to bio-
marker concentrations below and above the detection limit, half-
minimum and maximum values were imputed, respectively.
For the primary hypothesis, sequential multivariable linear
regression models were used to study associations between pre-
specified one-carbon metabolites (exposure) and inflammation-
and angiogenesis-related biomarkers (outcome). Models were
adjusted for (1) sex and age group (<60, 60–70, >70 years);
(2) model 1 plus BMI category (<25, 25–30, ≥30 kg/m2), smoking
status (current, former, never smoker), regularmultivitamin intake
in the month prior to surgery weekly (yes, no), CRC site (colon,
rectum), CRC stage (I, II, III) and physical activity (min/week).
Validity checks (tests for heteroscedasticity and multicollinearity)
for themultivariablemodelswere performed. Inclusion of alcohol
in themodel did not modify effect estimates more than 10%; thus,
it was excluded from the final models. We did not adjust for race/
ethnicity owing to our homogeneous non-Hispanic white
population.
In secondary analyses, regression models were stratified
by PLP sufficiency defined as ≥ 20 nmol/l(29), BMI and CRC
site (colon v. rectum). Effect modification was evaluated by
testing for the significance of an interaction term in the linear
regression models. We further calculated the PA:(PLPþ PL) ratio
(PAr index), an integrated measure of vitamin B6 metabolism
that has been proposed as a systemic inflammation indica-
tor(30,31), and evaluated its association with inflammation- and
angiogenesis-related biomarkers. Moreover, we calculated the
ratio of 3-hydroxykynurenine (HK):xanthurenic acid (XA),
both involved in tryptophan metabolism, (HK:XA ratio), as a
functional marker of vitamin B6 status(32). Finally, we stratified
the analyses of the association of inflammation biomarkers with
PLP and mTHF by BMI and by disease stage.
In exploratory analyses, we computed Spearman partial corre-
lation coefficients between inflammation-, angiogenesis-related, B
vitamins and one-carbon metabolism biomarkers, adjusting for
covariates. A Gaussian graphical model (GGM) was generated to
visualise correlated pathways among the analysed biomarkers,
conditioned on the presence of all other biomarkers. Conditional
correlations ≥|0·20| are displayed with an edge, connecting
biomarker nodes. The GGM is a powerful tool for visualising
metabolomics datasets and identifying relationships between
biological pathways(33). We further generated a hierarchical
clustering heat map to visualise pathway inter-relationships.
All statistical tests were two-sided. Statistical significance was
set at P< 0·05 for the primary and secondary hypotheses, and to
account for multiple testing in Spearman partial correlation
analyses, we considered significance at the Benjamini and
Hochberg’s False Discovery Rate (FDR) <0·05(34). With a sample
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size of 238, eighteen partial variables, and α= 0·0033 (to account
for analyses of three one-carbonmetabolites with five inflamma-
tory biomarkers for the primary and secondary hypotheses), we
estimated about 80 % statistical power to detect partial correla-
tions of r ~ 0·25. The statistical power calculations were con-
ducted using the Proc Power Multreg statement in SAS 9.4
(SAS Institute). Descriptive statistics, multivariable linear regres-
sion analyses and Spearman partial correlation analyses were
performed using SAS 9.4 (SAS Institute). GGMwas created using
R (R studio) and visualised using Cytoscape 3.6.1 (Cytoscape
Consortium) and the hierarchical clustering heat map with
BioVinci 1.1.5 (BioTuring Inc.).
Results
Study population
Baseline clinical and demographic characteristics of the study
population are summarised in Table 1. CRC patients in this study
(n 238) had a mean age of 64·4 (SD 12·1) years, were predomi-
nantly male (65 %), overweight (63 %) and ever smokers (63 %).
Only 6 % of participants regularly used multivitamin supple-
ments and 23 % used non-steroidal anti-inflammatory drugs in
the month prior to surgery, at least weekly. Approximately
50 % of CRC tumours were in the rectum or recto-sigmoid junc-
tion, 24·0 % of individuals were diagnosed with stage I, 40·3 %
stage II and 35·7 % stage III disease.
Mean values and standard deviations and medians and inter-
quartile ranges of inflammation- and angiogenesis-related bio-
markers, B vitamins and one-carbon metabolites are reported
in Table 2. Mean CRP and SAA concentrations were elevated
(27·5 (SD 51·7) and 42·5 (SD 73·0) mg/l, respectively) according
to clinical reference ranges (<10 mg/l)(35), indicative of active
systemic inflammation in our study population. Themedian con-
centration of circulating PLP was 26·5 nmol/l (interquartile range
17·1–40·8 nmol/l); 66 % of participants had sufficient PLP con-
centrations (≥20 nmol/l)(29).
Pyridoxal-5’-phosphate and inflammation
To evaluate our primary and secondary hypotheses, we per-
formed multivariable linear regression analyses (Table 3, Fig. 1).
Magnitude of association differed for minimally v. fully
adjusted models, but the directions of association were
unchanged. In fully adjusted models, PLP was significantly
inversely associated with inflammation biomarkers CRP
Table 1. Baseline clinicopathological and demographic characteristics of
238 colorectal cancer patients enrolled in the ColoCare Study*
(Mean values and standard deviations; median values and interquartile












WHO BMI categories (kg/m2)
<25 (Underweight and normal weight) 25 36·7
25–<30 (Overweight) 110 46·4








Current smoker 43 18·1
Former smoker§ 106 44·5







Rectum and recto-sigmoid junction 110 46·2
Moderate physical activity¶ (min/week)
Median 55
IQR 136·5
Vigorous physical activity¶ (min/week)
Median 0
IQR 57·0
* Percentages may not add to 100% due to missing values.
†Multivitamin intake is defined as1þ times/week ofmultivitamin use in the past 1month.
‡ Twenty patients had unknown information on multivitamin intake; twenty-three
patients had unknown smoking history.
§ Former smoker is defined as stopped smoking within the last 2 years.
¶ Moderatephysicalactivityreferstoactivities,whichrequiremoderateeffort,suchaswalking
or bicycling. Vigorous physical activity includes, for example, jogging or fast swimming.
Table 2. Biomarkers of inflammation, angiogenesis and one-carbon
metabolism among 238 colorectal cancer patients enrolled in the
ColoCare Study
(Mean values and standard deviations; median values and interquartile
ranges (IQR))
Biomarkers Mean SD Median IQR
Inflammation and angiogenesis
CRP (mg/l) 27·5 51·7 3·80 19·2
SAA (mg/l) 42·5 73·0 7·05 28·4
IL-6 (pg/ml) 4·46 20·2 0·79 1·30
IL-8 (pg/ml) 31·9 102 8·09 10·1
MCP-1 (pg/ml) 209 155 175 100
sICAM-1 (mg/l) 0·46 0·18 0·43 0·20
sVCAM-1 (mg/l) 0·64 0·30 0·59 0·27
TNFα (pg/ml) 1·23 0·89 1·16 0·69
VEGF-A (pg/ml) 841 541 749 559
VEGF-D (pg/ml) 836 304 799 314
B vitamins and one-carbon metabolites
mTHF (nmol/l) 22·4 14·4 18·8 14·0
Folic acid (nmol/l) 0·22 2·10 0·00 0·00
apABG (nmol/l) 1·28 2·22 0·85 0·54
pABG (nmol/l) 1·16 1·26 0·79 0·96
Cobalamin (pmol/l) 358 266 315 183
Thiamine (nmol/l) 8·25 7·02 6·94 4·50
TMP (nmol/l) 2·91 1·95 2·47 2·28
Riboflavin (nmol/l) 24·3 23·6 18·0 13·9
Total homocysteine (μmol/l) 13·3 5·45 12·3 6·07
PLP (nmol/l) 35·2 34·4 26·5 23·7
PL (nmol/l) 20·8 76·6 10·4 9·02
PA (nmol/l) 35·8 92·2 21·8 15·8
CRP, C-reactive protein; SAA, serum amyloid A; MCP-1, monocyte chemoattractant
protein 1; sICAM-1, soluble intercellular adhesion molecule 1; sVCAM-1, soluble
vascular cell adhesion molecule 1; VEGF, vascular endothelial growth factor; mTHF,
5-methyl-tetrahydrofolate; apABG, acetyl-para-aminobenzoylglutamic acid; pABG,
para-aminobenzoylglutamic acid; TMP, thiamin monophosphate; PLP, pyridoxal-5’-
phosphate; PL, pyridoxal; PA, pyridoxic acid.
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Table 3. Associations between one-carbon metabolites and inflammation biomarkers among 238 colorectal cancer patients enrolled in the ColoCare Study*




Simple† Full‡ Simple† Full‡
β 95% CI P β 95% CI P β 95% CI P β 95% CI P
CRP –0·98 –1·33, –0·64 <0·0001 –0·86 –1·24, –0·50 <0·0001 –0·58 –1·00, –0·16 0·007 –0·71 –1·18, –0·23 0·004
SAA –0·63 –0·96, –0·30 0·0002 –0·56 –0·94, –0·19 0·003 –0·52 –0·91, –0·12 0·01 –0·68 –1·13, –0·23 0·003
IL-8 –0·25 –0·45, –0·04 0·02 –0·26 –0·48, –0·04 0·02 –0·12 –0·36, 0·13 0·34 –0·16 –0·43, 0·11 0·24
IL-6 –0·74 –1·00, –0·48 <0·0001 –0·69 –0·97, –0·40 <0·0001 –0·20 –0·52, 0·13 0·24 –0·24 –0·60, 0·11 0·17




Simple† Full‡ Simple† Full‡
β 95% CI P β 95% CI P β 95% CI P β 95% CI P
CRP 0·10 –0·44, 0·64 0·71 0·05 –0·52, 0·63 0·90 0·29 –0·08, 0·66 0·13 0·39 –0·03, 0·80 0·07
SAA –0·14 –0·65, 0·37 0·59 –0·17 –0·72, 0·38 0·54 0·14 –0·20, 0·49 0·42 0·19 –0·20, 0·58 0·34
IL-8 –0·02 –0·33, 0·29 0·89 –0·04 –0·36, 0·28 0·82 0·67 0·46, 0·87 <0·0001 0·58 0·36, 0·81 <0·0001
IL-6 0·86 0·46, 1·25 <0·0001 0·93 0·53, 1·33 <0·0001 0·18 –0·10, 0·47 0·21 0·11 –0·20, 0·41 0·49
TNFα –0·07 –0·28, 0·13 0·48 –0·09 –0·31, 0·12 0·12 0·17 0·03, 0·32 0·02 0·12 –0·04, 0·27 0·13
PLP, pyridoxal-5’-phosphate; mTHF, 5-methyl-tetrahydrofolate; CRP, C-reactive protein; SAA, serum amyloid A; apABG, acetyl-para-aminobenzoylglutamic acid; pABG, para-aminobenzoylglutamic acid.
* Biomarker values were log2-transformed to meet the normality assumptions for linear regression models.
† Simple model: multivariable linear regression model, adjusted for: age group (<60, 60 to <70 and ≥70 years) and patient sex.
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(r –0·33, β= –0·86, Plinear< 0·0001), SAA (r –0·23, β= –0·56,
Plinear= 0·003), IL-6 (r –0·39, β= –0·69, Plinear< 0·0001), IL-8 (r –
0·20, β= –0·26, Plinear= 0·02) and TNFα (r –0·12, β= –0·15,
Plinear= 0·045).
Folate species and inflammation
mTHF showed significantly inverse associationswith CRP (r –0·14;
β= –0·71, Plinear= 0·004), SAA (r –0·14; β= –0·68, Plinear= 0·003)
and TNFα (r –0·15; β= –0·20, Plinear= 0·02). Folate catabolite
apABG was positively correlated with IL-6 (r 0·27; β= 0·93,
Plinear< 0·0001), and pABG was positively correlated with IL-8
(r 0·21; β= 0·58, Plinear< 0·0001). Folic acid, the synthetic form
of folate, was not associated with any inflammation biomarker
(P> 0·05 for all associations). In sensitivity analyses, we
additionally adjusted the primary analyses for non-steroidal anti-
inflammatory drugs use in the month prior to surgery, with similar
results.
Secondary analyses
In stratified analyses by serum PLP sufficiency (≥20 nmol/l), PLP
remained inversely associated with IL-6 among those with insuf-
ficient PLP concentrations (r –0·40; β= –1·14, Plinear= 0·03),
while the association was attenuated among those with PLP
sufficiency (r –0·22; β= –0·48,Plinear = 0·03). Magnitudes of asso-
ciation were similar for PLP and IL-8, stratified by PLP sufficiency
(PLP-insufficient: r –0·23; β= –0·28, Plinear= 0·5; PLP-sufficient:
r –0·19; β= –0·37, Plinear = 0·05). Moreover, the results suggested
that the associations of PLP with CRP may differ by BMI and
CRC stage, but the P values for heterogeneity did not reach stat-
istical significance (Pheterogeneity = 0·07 and 0·09, respectively)
(Table 4). For example, there was a stronger inverse association
between PLP and CRP among normoweight (r –0·39; β= –1·45,
Plinear= 0·0008), compared with overweight participants (r –0·19;
β= –0·54, Plinear= 0·03, Phet= 0·02). The magnitude of inverse
associations between PLP and CRP was stronger among patients
with stage I (r –0·53; β= –2·02, Plinear< 0·0001), compared
with stage II (r –0·31; β= –0·72, Plinear= 0·02, Phet= 0·20) and
stage III (r –0·20; β= –0·44, Plinear= 0·20, Phet= 0·03) disease.
Moreover, there was evidence for effect modification of mTHF
associations with TNFα by BMI; the association was stronger
for overweight individuals (Phet= 0·009), but the same was
not observed for under/normal-weight or obese individuals
(Table 5). The inverse association of mTHF with both CRP and
SAA appeared to be stronger among those with earlier stage
disease (Phet= 0·02).
The PAr index showed positive associations with IL-6 (r 0·18;
β= 0·57, Plinear= 0·004), IL-8 (r 0·18; β= 0·36, Plinear= 0·02) and
TNFα (r 0·15; β= 0·20, Plinear= 0·04); associations with CRPwere
positive but not statistically significant (r 0·11; β= 0·36,
Plinear= 0·20) or SAA (r 0·08; β= 0·26, Plinear= 0·30). The HK:
XA ratio was positively associated with CRP (r 0·46; β= 1·16,
Plinear< 0·0001), SAA (r 0·38; β= 0·83, Plinear< 0·0001) and
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Fig. 1. Scatter plots of one-carbon metabolite pyridoxal-5’-phosphate (PLP) and inflammation biomarkers C-reactive protein (CRP) (a), IL-6 (b), IL-8 (c) and serum
amyloid A (SAA) (d) based on univariate linear regression. The represented biomarkers were log2-transformed to meet the normality assumption for linear regression.
Single biomarker values are visualised in grey and the regression line in black. This figure was created with GraphPad Prism8.
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Table 4. Associations of active vitamin B6 (pyridoxal-5’-phosphate) with inflammation biomarkers, stratified by BMI and cancer stage among 238 colorectal cancer patients enrolled in
the ColoCare Study*




weight <25 kg/m2 (n 87)
Overweight
25 to <30 kg/m2 (n 110)
Obese
30þ kg/m2 (n 40) P for heterogeneity




weight v. obese Overall
CRP –1·45 –2·26, –0·63 0·0008 –0·54 –1·02, –0·06 0·03 –1·03 –2·89, 0·82 0·25 0·02 0·52 0·07
SAA –1·21 –1·90, –0·52 0·0009 –0·34 –0·82, 0·15 0·17 –0·77 –3·06, 1·53 0·48 0·03 0·29 0·10
IL-8 –0·48 –0·85, –0·11 0·01 –0·18 –0·52, –0·16 0·29 –0·33 –1·17, 0·52 0·43 0·28 0·43 0·51
IL-6 –0·57 –1·13, –0·02 0·04 –0·65 –1·07, –0·23 0·003 –0·72 –1·36, –0·08 0·03 0·94 0·56 0·83
TNFα –0·07 –0·33, 0·20 0·61 –0·13 –0·32, 0·06 0·18 –0·49 –1·01, 0·03 0·06 0·61 0·28 0·36
Inflammation biomarkers
Cancer stage†
Stage I (n 57) Stage II (n 96) Stage III (n 85) P for heterogeneity
β 95% CI P β 95% CI P β 95% CI P I v. II I v. III Overall
CRP –2·02 –2·83, –1·19 <0·0001 –0·72 –1·33, –0·11 0·02 –0·44 –1·18, 0·29 0·23 0·22 0·03 0·09
SAA –1·42 –2·32, –0·52 0·003 –0·49 –1·08, 1·11 0·11 –0·30 –1·02, 0·42 0·41 0·39 0·32 0·58
IL-8 –0·58 –1·15, –0·02 0·04 –0·12 –0·49, 0·25 0·52 –0·32 0·71, 0·07 0·10 0·55 0·91 0·78
IL-6 –1·21 –2·0, –0·44 0·003 –0·54 –0·92, –0·15 0·007 –0·56 –1·09, –0·02 0·04 0·05 0·15 0·14
TNFα –0·38 –0·79, 0·02 0·06 –0·17 –0·43, 0·09 0·19 –0·07 –0·30, 0·15 0·52 0·35 0·26 0·51
CRP, C-reactive protein; SAA, serum amyloid A.
* Biomarker values were log2-transformed to meet the normality assumptions for linear regression models.
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Table 5. Associations of active folate species (5-methyl-tetrahydrofolate) with inflammation biomarkers, stratified by BMI and cancer stage among 238 colorectal cancer patients enrolled
in the ColoCare Study*




weight <25 kg/m2 (n 87)
Overweight
25 to <30 kg/m2 (n 110)
Obese
30þ kg/m2 (n 40) P for heterogeneity




weight v. obese Overall
CRP –0·81 –1·65, 0·02 0·06 –0·22 –0·95, 0·5 0·50 –0·96 –2·64, 0·71 0·24 0·30 0·68 0·43
SAA –0·78 –1·48, –0·08 0·03 –0·26 –0·99, 0·48 0·50 –1·33 –3·29, 0·64 0·17 0·25 0·62 0·35
IL-8 –0·32 –0·7, 0·06 0·10 –0·26 –0·73, 0·2 0·27 0·47 –0·3, 1·24 0·22 0·86 0·08 0·20
IL-6 –0·49 –1·05, 0·08 0·09 –0·13 –0·75, 0·48 0·70 0·47 –0·16, 1·11 0·14 0·34 0·11 0·26
TNFα –0·03 –0·29, 0·24 0·84 –0·48 –0·73, –0·24 0·0002 –0·04 –0·57, 0·48 0·86 0·004 0·95 0·009
Inflammation biomarkers
Cancer stage†
Stage I (n 57) Stage II (n 96) Stage III (n 85) P for heterogeneity
β 95% CI P β 95% CI P β 95% CI P I v. II I v. III Overall
CRP –1·41 –2·2, –0·62 0·0009 0·002 –0·68, 0·68 0·99 –0·22 –1·48, –1·04 0·73 0·01 0·03 0·02
SAA –1·31 –2·1, –0·55 0·001 –0·14 –0·8, 0·5 0·67 –0·42 –1·64, 0·79 0·49 0·01 0·03 0·02
IL-8 –0·51 –0·98, –0·03 0·04 –0·002 –0·41, 0·41 0·99 –0·27 –0·86, 0·33 0·37 0·28 0·30 0·48
IL-6 –0·76 –1·45, –0·06 0·03 –0·04 –0·48, 0·40 0·90 0·07 –0·77, 0·90 0·88 0·04 0·03 0·05
TNFα –0·3 –0·65, 0·04 0·08 –0·18 –0·47, 0·10 0·20 –0·06 –0·40, 0·29 0·75 0·70 0·65 0·89
CRP, C-reactive protein; SAA, serum amyloid A.
* Biomarker values were log2-transformed to meet the normality assumptions for linear regression models.
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also positive but not statistically significant (r 0·21; β= 0·13,
Plinear= 0·20) or TNFα (r 0·13; β= 0·06, Plinear= 0·40).
Exploratory analyses
In exploratory analyses, we evaluated partial correlations
between the full panel of circulating biomarkers (online
Supplementary Table S1). Forty-two partial correlations reached
the FDR significance threshold of <0·05. For example, PL was
inversely correlated with CRP (r –0·29, P< 0·001), IL-6 (r –0·30,
P< 0·001) and VEGF-D (r 0·23, P= 0·002).We also noted positive
correlations between pABG and VEGF-D (r 0·27, P= 0·0003) and
between total homocysteine and VEGF-D (r 0·31, P< 0·001).
Thiamine and thiamine monophosphate were inversely corre-
lated with CRP (r –0·20, P< 0·001 and r –0·35, P< 0·001) and
IL-6 (r –0·38, P< 0·001 and r –0·33, P< 0·001), while thiamine
monophosphatewas inversely correlatedwith SAAandmonocyte
chemoattractant protein 1 (r –0·27, P< 0·001 and r –0·18,
P= 0·01, respectively). In contrast, correlations between cobala-
min (vitamin B12) and biomarkers of inflammation were positive,
but not statistically significant at FDR< 0·05.
Biomarker intercorrelationswere visualised using a hierarchi-
cal clustering heat map (Fig. 2) and GGM (Fig. 3). The GGM
showed a single interconnected network between B vitamins,
one-carbon metabolites and angiogenesis- and inflammation-
related biomarkers, including inverse conditional correlations
of PLP with IL-6, PL and SAA. The GGM visualises correlations
conditional on the presence of all other biomarkers, with a
threshold (r |0·20|) for connecting nodes with edges.
Discussion
In this study, we measured associations between one-carbon
metabolites, inflammation- and angiogenesis-related biomarkers
in a cross-sectional analysis among CRC patients participating in
the ColoCare Study. We found that vitamin B6 species, PLP, PL
and PA,were inversely associatedwith inflammatory biomarkers
CRP, SAA, IL-6 and IL-8. Thiamine and active folate were also
inversely associated with inflammatory biomarkers, and folate
catabolites were positively associated with inflammation, indi-
cating higher folate utilisation.
PLP is the bioactive form of vitamin B6, an essential vitamin
that may be obtained from many sources including fortified cer-
eals, milk products, beans, nuts and vitamin supplements(29,30).
PL represents the dephosphorylated form of PLP, and PA derives
from PLP in an oxidation reaction with aldehyde oxidase I(31).
PLP serves as a coenzyme in over 4 % of human metabolic
reactions(30), including preventing the formation of reactive
oxygen species(30). Inverse associations of vitamin B6 intake
and circulating PLP with CRC risk have been reported(18,36,37).
The relationship of PLPwith CRC outcomes is less established(38).
An inverse association between PLP and inflammatory bio-
markers was previously reported among postmenopausal
women in the Women’s Health Initiative Observational
Study(15), among healthy adults in the Boston Puerto Rican
Health Study(20) and FraminghamHeart Study(19), and in patients
with chronic inflammatory conditions, such as depression and
inflammatory bowel disease(39,40). In a prior intervention trial
among rheumatoid arthritis patients, vitamin B6 supplementa-
tion suppressed IL-6 and TNFα concentrations(41). In our study,
we also noted that participants with increased CRP concentra-
tions (>10 mg/l) were less PLP-sufficient than those within the
physiological range of CRP. Similar findings were described
among 2686 adults in the US National Health & Nutrition
Examination Survey(42). Our results corroborate prior findings
and show that these processes additionally apply to CRC



































































Fig. 2. Hierarchical clustering heat map, based on Spearman partial correlations of B vitamins and one-carbon metabolites with inflammation and angiogenesis
biomarkers, adjusted for age group, patient sex, BMI category, cancer stage and site, physical activity, multivitamin intake and smoking status. Biomarkers involved
in the same or similar pathways (such as pyridoxal (PL), pyridoxic acid (PA) and pyridoxal-5’-phosphate (PLP)) cluster together in the heat map. Blue indicates inverse
correlations, for example, between PLP and C-reactive protein (CRP). Orange and red represent positive correlations, for example, between CRP and serum amyloid
A (SAA). This heat map was created with BioVinci 1.1.5 (BioTuring Inc.). sICAM-1, soluble intercellular adhesion molecule 1; sVCAM-1, soluble vascular cell adhesion
molecule 1; MCP-1, monocyte chemoattractant protein 1; TMP, thiamin monophosphate; Thi, thiamin; pABG, para-aminobenzoylglutamic acid; Ribo, riboflavin; apABG,
acetyl-pABG; mTHF, 5-methyl-tetrahydrofolate; FA, folic acid; tHcy, total homocysteine; VEGF, vascular endothelial growth factor; Cob, cobalamin.
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association between other one-carbon metabolites and inflam-
mation among CRC patients.
Our observations may reflect a modified distribution and
utilisation of PLP in serum during inflammatory processes, rather
than hypovitaminosis(30,43). PLP is stored predominantly in
muscle and liver. During inflammation, PLP is preferentially
mobilised from the liver. Due to the high demand of PLP by
enzymes involved in the inflammatory response, circulating
concentration may decrease(43). Alternately, a recent study
suggested that vitamin B6 species could inhibit the activation
of NF-κB, which is involved in the inflammatory response,
and nucleotide-binding oligomerisation domain, Leucine-rich
Repeat and Pyrin domain containing-mediated caspase-1 activa-
tion, which suppresses cytokine production(44). Postulated
anti-inflammatory mechanisms relevant for CRC patients include
activation of p53 and p21 tumour suppressor gene expression in
the colon(45,46). Moreover, human colon carcinoma cell line
studies demonstrated that vitamin B6 induced a reduction in
inflammatory cytokine (including IL-6 and TNFα) secretion from
peripheral blood mononuclear cells(47).
Our findings do not support strong effect modification of the
cross-sectional relationship between PLP and inflammation by
BMI or CRC stage, but it is possible that our studywas underpow-
ered to observe effect modification. Nonetheless, a trend was
apparent suggesting that advancing stage of CRC and increasing
BMI weakened the association between markers of inflamma-
tion and B vitamins/one-carbon metabolites. Specifically, the
inverse relationship of PLP with inflammation biomarkers
appeared stronger among normal-weight compared with over-
weight or obese participants. Similarly, it appeared stronger
among those with earlier stage disease, although results were
not statistically significant. The same heterogeneity according
to disease stage was apparent for the association of mTHF with
CRP and SAA. This might suggest that normal associations
become increasingly perturbed with advancing disease and
adiposity. Indeed, both obesity and cancer stage have been
shown to promote systemic inflammation(4,48–50).
We observed positive associations between the PAr index
(PA/(PL þ PLP)) and inflammation biomarkers, supporting
prior findings(30,31,51,52). As a systemic inflammation indicator(31),
Fig. 3. Gaussian graphical model (GGM) of biomarker correlations, conditioned on the presence of all other biomarkers (conditional r ≥|0·20|). Biomarkers are repre-
sented by nodes (circles), and conditional correlations are connected by edges (lines). Orange nodes represent inflammation, yellow nodes represent angiogenesis
biomarkers and green nodes represent B vitamins and one-carbon metabolites. The line width represents the strength of conditional correlation. Red lines indicate
positive correlations, and blue lines represent inverse correlations. Vascular endothelial growth factor A (VEGF-A) conditional r< 0·20. The GGM was created with
Cytoscape 3.6.1 (CytoscapeConsortium). sICAM-1, soluble intercellular adhesionmolecule 1; MCP-1, monocyte chemoattractant protein 1; sVCAM-1, soluble vascular
cell adhesion molecule 1; PLP, pyridoxal-5’-phosphate; PA, pyridoxic acid; PL, pyridoxal; apABG, acetyl-para-aminobenzoylglutamic acid; mTHF, 5-methyl-tetrahydro-
folate; pABG, para-aminobenzoylglutamic acid; FA, folic acid; tHcy, total homocysteine; Thi, thiamin; TMP, thiamin monophosphate; Ribo, riboflavin; Cob, cobalamin;
CRP, C-reactive protein; SAA, serum amyloid A.
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the PAr index is an independent predictor of stroke(51) and
cardiovascular mortality(53). Furthermore, we observed strong
positive associations between HK:XA ratio, a marker of func-
tional vitamin B6 status(32), and several inflammation biomarkers
(in particular the acute-phase proteins CRP and SAA). PAr index
and HK:XA ratio may represent alternative biomarkers for iden-
tifying those who might benefit from anti-inflammatory dietary
intervention.
Our findings suggest increased folate catabolism during
inflammation among CRC patients given that elevated inflam-
matory state was associated with higher folate catabolite con-
centrations in parallel with lower mTHF concentration. Prior
interventions of mTHF infusion among haemodialysis patients
demonstrated reduced circulating CRP(54). As excretion prod-
ucts, pABG and apABG are indicators of folate catabolism
and status(55) and would be expected to increase in response
to higher folate utilisation during inflammatory processes.
This observation of increased folate metabolism in relation to
inflammation may be important for informing future studies
designed to understand folate metabolism in the context of
CRC. A meta-analysis of nine randomised controlled FA inter-
vention trials (n 1179 adults) reported decreased serum CRP
post-intervention(56). These data were partially supported by
an analysis within the Women’s Health Initiative Observa-
tional Study cohort that showed a positive association of folate
status with SAA, but not with CRP(15). However, the Aspirin/
Folate Polyp Prevention Trial did not observe a significant
decrease of CRP, IL-6 or TNFα among participants receiving
FA(57). Whether folate’s influence on inflammation plays a
causal role in CRC is unclear. Rapidly proliferating cancer cells
have higher folate requirements to accommodate accelerated
DNA synthesis(58), though a dual modulatory effect on cancer
risk has been observed according to dosage and timing(59–62).
Folate may prevent CRC among subjects with a healthy colon,
but increase risk among those with colon premalignant
lesions(59–63), although these findings have been inconsistent(17).
Unlike in other countries, food products in Germany are not
fortified with FA. Moreover, the prevalence of supplement use in
our population was very low. We did not observe synthetic FA
associations with inflammation biomarkers. In contrast to dietary
folate, FA is not metabolised immediately to active mTHF. The
role of circulating unmetabolised FA in health remains under
debate(64). Future studies among CRC populations should
consider the roles of synthetic FA in comparison with the active
form mTHF in inflammatory processes.
We observed positive correlations of PA, PL and PLP with
angiogenesis biomarker VEGF-D, a cytokine involved in
blood vessel formation(13). Prior studies have found an inverse
association between these metabolites and angiogenesis
biomarkers(65,66). Hypothesised mechanisms include inhibition
of DNA topoisomerases and DNA polymerase by PLP(65,66).
In a study measuring mRNA expression levels of VEGF-A,
VEGF-C and VEGF-D and their receptors VEGFR-2 and
VEGFR-3 in seventy CRC (thirty-five with paired mucosae)
and twenty adenomatous polyps, it was found that VEGF-D
mRNA expression was significantly lower in both polyps and
CRC compared with normal mucosa but VEGF-A and VEGF-C
were significantly raised in CRC. It was postulated that decreased
VEGF-D may enable higher levels of VEGF-A and VEGF-C
to bind readily to the VEGF receptors, promoting tumour
growth(67). Therefore, our observation that vitamin Bmetabolites
were associatedwith VEGF-D but not VEGF-Amight suggest that
PLP associates with an anti-angiogenic microenvironment.
We observed inverse correlations between thiamine
(vitamin B1) and its metabolite thiamine monophosphate with
inflammation and angiogenesis biomarkers. Vitamin B1 plays a
key role in supporting enzymes involved in cellular and carbohy-
drate metabolism and has been shown to inhibit cell growth(68).
Thiamine supplementation trials have shown mixed results with
respect to inflammationbiomarkers(69,70), possibly due to the short
intervention duration (1month)(70), or thiamine deficiency at
baseline(71). Preclinical studies have demonstrated elevated
TNFα in thiamine-deficient mice(72) and reduced TNFα and IL-6
after thiamine administration(73). Hypothesised mechanisms for
thiamine’s anti-inflammatory potential include inhibition of
mitogen-activated protein kinase (MAPK) signalling, a key inflam-
matory pathway(74).
Total homocysteine was positively correlated with TNFα and
VEGF-D. These findings support prior observations of homocys-
teine associations with inflammation(75). The inverse association
of total homocysteine with IL-6 is not in line with prior
studies(76,77) and warrants investigation. However, IL-6 has been
suggested to play both anti- and pro-inflammatory roles(78,79).
Our study utilised rigorously collected data from the well-
established ColoCare Study, including state-of-the-art and highly
reproducible biomarker measurements. Our results support
prior findings of associations between some B vitamins and
inflammation biomarkers but apply these findings to a CRC
patient population. The current study also expands on prior
work by measuring a more comprehensive panel of one-carbon
and inflammatory biomarkers, in addition to angiogenesis
biomarkers. Although cross-sectional, our observations of a rela-
tionship between B vitamins and angiogenesis biomarkers are
novel and warrant further investigation in future prospective
studies. The dietary intake of CRC patients might change after
diagnosis depending on cancer treatment and on lifestyle modi-
fication. Considering that blood was drawn in our study within
days of surgery and that B-vitamin half-lives are relatively long
(e.g. 25 d for PLP(80)), it is unlikely that dietary intake changed
substantially in this period to affect circulating vitamin status.
We note some study limitations. Study participants were
predominantly non-Hispanic white; thus, studies in diverse
populations are warranted to enhance generalisability. Our
inflammatory biomarker panel did not include potentially anti-
inflammatory cytokines like IL-10. IL-10 has been shown to
both associate with CRC tumour progression and to inhibit
tumour growth depending on host immunity(81). Further
investigation of the relationship between both IL-10 and CRC
progression, and between IL-10 and B vitamins like PLP, may
shed further light on this relationship. Finally, the cross-sectional
study design precludes causal inference; therefore, results
should be interpreted with caution and further studies are
needed to determine the relevance of our observations to CRC
outcomes.
In conclusion, our study showed that PLP and folate species
within the one-carbon metabolism pathway are associated with
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both inflammation and angiogenesis pathways among CRC
patients. These findings reinforce the notion that B vitamins
involved in the one-carbon metabolism may be correlated with
carcinogenic processes. Prospective studies are needed to deter-
minewhether modulation of B-vitamin status leads to changes in
inflammation or angiogenesis pathways among CRC patients,
and the influence on CRC prognosis to further reinforce
B-vitamin status as a target for future dietary guidance in this
population.
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